Inhibrx secures $75M loan as earnings miss weighs on shares
Biotech cuts R&D spending 45% and eyes Q2 BLA submission for ozekibart cancer treatment
Inhibrx Biosciences shares fell sharply after the clinical-stage biotechnology company reported quarterly results that missed analyst expectations, though management moved to shore up its balance sheet with a $75 million financing facility from Oxford Finance.
The San Diego-based company reported a loss of $2.11 per share for the fourth quarter, wider than the $1.72 loss anticipated by analysts, according to regulatory filings. However, investors in pre-revenue biotechs typically focus more on cash runway and regulatory catalysts than near-term earnings, and Inhibrx delivered on both fronts.
The Oxford Finance loan, secured March 18, brings the company's total cash position to approximately $199 million, extending its runway into 2027. More significantly, Inhibrx reduced research and development spending by 45% year-over-year to $113 million, demonstrating operational discipline as it advances its lead program toward regulatory submission.
"The reduction in R&D expenses reflects a more disciplined approach to capital allocation," analysts noted, as the company prepares for a Biologics License Application (BLA) submission for ozekibart in chondrosarcoma expected in early Q2 2026. Chondrosarcoma is a rare bone cancer with limited treatment options, representing an orphan drug opportunity if approved.
The stock has declined 16% from $82 in February to $68.69, with shares trading at $64.87 at market close on March 19. The pullback has pushed the Relative Strength Index to 40.85, approaching oversold territory that some technical analysts view as a potential entry point ahead of the upcoming BLA catalyst.
Market sentiment remains cautious, with analysts assigning a consensus target price of $12.00, well below current levels—a reflection of the binary risks inherent in clinical-stage drug development. Recent insider selling has also weighed on investor confidence, according to MarketBeat data.
The stock remains volatile, trading 83% below its 52-week high of $94.56 set earlier this year, but still 500% above its 52-week low of $10.80. With 85.2% of shares held by institutional investors, the upcoming BLA submission will be closely watched by large shareholders who have largely maintained positions through recent volatility.
Inhibrx's $1 billion market capitalization and price-to-sales ratio of 719.5 reflect investor optimism about ozekibart's commercial potential, despite the company having generated just $1.4 million in trailing twelve-month revenue. The high multiple is typical of pre-revenue biotechs with late-stage assets in rare diseases with high unmet medical need.
The Q2 2026 BLA submission represents the most significant near-term catalyst for the stock. If approved, ozekibart would become Inhibrx's first commercial product, transforming the company from a clinical-stage developer to a commercial biopharmaceutical enterprise with a rare disease therapy.
Until then, investors will focus on the company's ability to execute on its regulatory timeline and manage its cash burn rate. The $75 million loan and reduced R&D spending provide additional buffer, but the binary nature of FDA decisions means volatility is likely to persist as the submission date approaches.